As demonstrated previously56–58, PFS was statistically significantly prolonged in both the intention-to-treat (ITT) population and the PD-L1 positive population (≥1% expression on immune cells in the tumor area) in the atezolizumab arm. The gene discussed is CD274; the disease is neoplasm.